Close Menu

NEW YORK – Australian genetic testing firm Genetic Technologies said on Wednesday it has entered into definitive agreements with unnamed institutional investors for the purchase of more than 1 million American Depositary Shares at A$1.75 ($1.07) per ADS in a registered direct offering.

Each ADS represents 600 of the firm's ordinary shares, and gross proceeds from the offering, expected to close on or about April 3, is estimated at A$1.8 million ($1.1 million).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.